Puma Biotechnology (PBYI)
(Delayed Data from NSDQ)
$5.02 USD
+0.14 (2.87%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $5.01 -0.01 (-0.20%) 7:58 PM ET
4-Sell of 5 4
A Value A Growth C Momentum A VGM
Balance Sheet
Fiscal Year End for Puma Biotechnology, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 96 | 81 | 91 | 102 | 121 |
Receivables | 48 | 40 | 33 | 26 | 29 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 7 | 5 | 7 | 3 | 3 |
Other Current Assets | 5 | 8 | 9 | 15 | 14 |
Total Current Assets | 156 | 134 | 140 | 146 | 166 |
Net Property & Equipment | 1 | 1 | 2 | 2 | 3 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 61 | 71 | 66 | 74 | 40 |
Deposits & Other Assets | 5 | 5 | 5 | 5 | 6 |
Total Assets | 231 | 222 | 227 | 244 | 235 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 6 | 11 | 12 | 19 |
Current Portion Long-Term Debt | 34 | 0 | 0 | 14 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 53 | 66 | 93 | 82 | 69 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 1 | 2 | 2 | 0 |
Total Current Liabilities | 99 | 77 | 110 | 114 | 91 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 66 | 98 | 97 | 84 | 95 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 13 | 6 | 32 | 9 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 177 | 200 | 229 | 250 | 217 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,399 | 1,388 | 1,364 | 1,332 | 1,295 |
Retained Earnings | -1,345 | -1,367 | -1,367 | -1,338 | -1,278 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 53 | 22 | -2 | -6 | 17 |
Total Liabilities & Shareholder's Equity | 231 | 222 | 227 | 244 | 235 |
Total Common Equity | 53 | 22 | -2 | -6 | 17 |
Shares Outstanding | 47.50 | 45.60 | 40.80 | 39.70 | 38.90 |
Book Value Per Share | 1.13 | 0.47 | -0.06 | -0.15 | 0.45 |
Fiscal Year End for Puma Biotechnology, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 96 | 85 | 74 | 71 |
Receivables | NA | 48 | 29 | 31 | 31 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 7 | 6 | 8 | 4 |
Other Current Assets | NA | 5 | 6 | 5 | 5 |
Total Current Assets | NA | 156 | 125 | 119 | 112 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 61 | 63 | 66 | 68 |
Deposits & Other Assets | NA | 5 | 6 | 5 | 5 |
Total Assets | NA | 231 | 204 | 200 | 196 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 7 | 5 | 8 | 9 |
Current Portion Long-Term Debt | NA | 34 | 23 | 11 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 53 | 34 | 36 | 34 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 1 | 1 | 1 | 1 |
Total Current Liabilities | NA | 99 | 67 | 60 | 48 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 66 | 77 | 88 | 99 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 13 | 13 | 13 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 177 | 165 | 170 | 170 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 1,399 | 1,396 | 1,394 | 1,391 |
Retained Earnings | NA | -1,345 | -1,357 | -1,363 | -1,365 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 53 | 39 | 30 | 26 |
Total Liabilities & Shareholder's Equity | NA | 231 | 204 | 200 | 196 |
Total Common Equity | 0 | 53 | 39 | 30 | 26 |
Shares Outstanding | 48.20 | 47.50 | 47.50 | 46.70 | 46.60 |
Book Value Per Share | 0.00 | 1.13 | 0.82 | 0.65 | 0.55 |